nodes	percent_of_prediction	percent_of_DWPC	metapath
Atomoxetine—HTR2A—phrenic nerve—amyotrophic lateral sclerosis	0.0427	0.12	CbGeAlD
Atomoxetine—Major depression—Riluzole—amyotrophic lateral sclerosis	0.0366	0.0705	CcSEcCtD
Atomoxetine—NPY1R—nerve—amyotrophic lateral sclerosis	0.0279	0.0784	CbGeAlD
Atomoxetine—HTR1B—cranial nerve—amyotrophic lateral sclerosis	0.0231	0.0649	CbGeAlD
Atomoxetine—HTR1D—cranial nerve—amyotrophic lateral sclerosis	0.0224	0.0628	CbGeAlD
Atomoxetine—Hostility—Riluzole—amyotrophic lateral sclerosis	0.0178	0.0343	CcSEcCtD
Atomoxetine—Micturition urgency—Riluzole—amyotrophic lateral sclerosis	0.0174	0.0335	CcSEcCtD
Atomoxetine—Suicide attempt—Riluzole—amyotrophic lateral sclerosis	0.0174	0.0335	CcSEcCtD
Atomoxetine—Completed suicide—Riluzole—amyotrophic lateral sclerosis	0.0168	0.0323	CcSEcCtD
Atomoxetine—Myoclonus—Riluzole—amyotrophic lateral sclerosis	0.0164	0.0316	CcSEcCtD
Atomoxetine—Upset stomach—Riluzole—amyotrophic lateral sclerosis	0.015	0.029	CcSEcCtD
Atomoxetine—Mania—Riluzole—amyotrophic lateral sclerosis	0.0135	0.0261	CcSEcCtD
Atomoxetine—SLC6A3—nerve—amyotrophic lateral sclerosis	0.0118	0.033	CbGeAlD
Atomoxetine—Delirium—Riluzole—amyotrophic lateral sclerosis	0.0115	0.0221	CcSEcCtD
Atomoxetine—HTR2A—cranial nerve—amyotrophic lateral sclerosis	0.0111	0.0312	CbGeAlD
Atomoxetine—HTR2A—pons—amyotrophic lateral sclerosis	0.011	0.0308	CbGeAlD
Atomoxetine—Bone disorder—Riluzole—amyotrophic lateral sclerosis	0.0109	0.021	CcSEcCtD
Atomoxetine—Abnormal dreams—Riluzole—amyotrophic lateral sclerosis	0.00973	0.0188	CcSEcCtD
Atomoxetine—SLC6A2—nerve—amyotrophic lateral sclerosis	0.00948	0.0266	CbGeAlD
Atomoxetine—HTR2A—hindlimb—amyotrophic lateral sclerosis	0.00937	0.0263	CbGeAlD
Atomoxetine—Coma—Riluzole—amyotrophic lateral sclerosis	0.009	0.0174	CcSEcCtD
Atomoxetine—SLC6A3—hindbrain—amyotrophic lateral sclerosis	0.0088	0.0247	CbGeAlD
Atomoxetine—SLC6A4—hindbrain—amyotrophic lateral sclerosis	0.00807	0.0226	CbGeAlD
Atomoxetine—HTR2A—appendage—amyotrophic lateral sclerosis	0.00804	0.0226	CbGeAlD
Atomoxetine—Libido decreased—Riluzole—amyotrophic lateral sclerosis	0.00771	0.0149	CcSEcCtD
Atomoxetine—Thirst—Riluzole—amyotrophic lateral sclerosis	0.00751	0.0145	CcSEcCtD
Atomoxetine—HTR2A—peripheral nervous system—amyotrophic lateral sclerosis	0.00731	0.0205	CbGeAlD
Atomoxetine—Disturbance in sexual arousal—Riluzole—amyotrophic lateral sclerosis	0.00709	0.0137	CcSEcCtD
Atomoxetine—Affect lability—Riluzole—amyotrophic lateral sclerosis	0.00704	0.0136	CcSEcCtD
Atomoxetine—Psychotic disorder—Riluzole—amyotrophic lateral sclerosis	0.00698	0.0135	CcSEcCtD
Atomoxetine—Urinary retention—Riluzole—amyotrophic lateral sclerosis	0.0068	0.0131	CcSEcCtD
Atomoxetine—Mood swings—Riluzole—amyotrophic lateral sclerosis	0.00677	0.0131	CcSEcCtD
Atomoxetine—Breast disorder—Riluzole—amyotrophic lateral sclerosis	0.00646	0.0125	CcSEcCtD
Atomoxetine—NPY1R—nervous system—amyotrophic lateral sclerosis	0.00628	0.0176	CbGeAlD
Atomoxetine—Influenza—Riluzole—amyotrophic lateral sclerosis	0.00618	0.0119	CcSEcCtD
Atomoxetine—NPY1R—central nervous system—amyotrophic lateral sclerosis	0.00605	0.017	CbGeAlD
Atomoxetine—Abdominal discomfort—Riluzole—amyotrophic lateral sclerosis	0.00592	0.0114	CcSEcCtD
Atomoxetine—Dysuria—Riluzole—amyotrophic lateral sclerosis	0.00578	0.0111	CcSEcCtD
Atomoxetine—Pollakiuria—Riluzole—amyotrophic lateral sclerosis	0.00571	0.011	CcSEcCtD
Atomoxetine—HTR2A—nerve—amyotrophic lateral sclerosis	0.0057	0.016	CbGeAlD
Atomoxetine—Erectile dysfunction—Riluzole—amyotrophic lateral sclerosis	0.00569	0.011	CcSEcCtD
Atomoxetine—Fluoxetine—SIGMAR1—amyotrophic lateral sclerosis	0.00561	0.781	CrCbGaD
Atomoxetine—Weight decreased—Riluzole—amyotrophic lateral sclerosis	0.00559	0.0108	CcSEcCtD
Atomoxetine—Infestation NOS—Riluzole—amyotrophic lateral sclerosis	0.00551	0.0106	CcSEcCtD
Atomoxetine—Infestation—Riluzole—amyotrophic lateral sclerosis	0.00551	0.0106	CcSEcCtD
Atomoxetine—Depression—Riluzole—amyotrophic lateral sclerosis	0.00549	0.0106	CcSEcCtD
Atomoxetine—Sinusitis—Riluzole—amyotrophic lateral sclerosis	0.00517	0.00997	CcSEcCtD
Atomoxetine—HTR1B—brainstem—amyotrophic lateral sclerosis	0.00509	0.0143	CbGeAlD
Atomoxetine—SLC6A3—brainstem—amyotrophic lateral sclerosis	0.00505	0.0142	CbGeAlD
Atomoxetine—HTR1D—brainstem—amyotrophic lateral sclerosis	0.00493	0.0138	CbGeAlD
Atomoxetine—Hallucination—Riluzole—amyotrophic lateral sclerosis	0.00492	0.00949	CcSEcCtD
Atomoxetine—Hypoaesthesia—Riluzole—amyotrophic lateral sclerosis	0.00492	0.00949	CcSEcCtD
Atomoxetine—Urinary tract disorder—Riluzole—amyotrophic lateral sclerosis	0.00488	0.00942	CcSEcCtD
Atomoxetine—HTR2C—brainstem—amyotrophic lateral sclerosis	0.00488	0.0137	CbGeAlD
Atomoxetine—Urethral disorder—Riluzole—amyotrophic lateral sclerosis	0.00485	0.00935	CcSEcCtD
Atomoxetine—NPY1R—brain—amyotrophic lateral sclerosis	0.0048	0.0135	CbGeAlD
Atomoxetine—SLC6A4—brainstem—amyotrophic lateral sclerosis	0.00462	0.013	CbGeAlD
Atomoxetine—Cardiac disorder—Riluzole—amyotrophic lateral sclerosis	0.00459	0.00886	CcSEcCtD
Atomoxetine—Angiopathy—Riluzole—amyotrophic lateral sclerosis	0.00449	0.00866	CcSEcCtD
Atomoxetine—Mediastinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00446	0.0086	CcSEcCtD
Atomoxetine—Chills—Riluzole—amyotrophic lateral sclerosis	0.00444	0.00856	CcSEcCtD
Atomoxetine—HTR6—nervous system—amyotrophic lateral sclerosis	0.00442	0.0124	CbGeAlD
Atomoxetine—Mental disorder—Riluzole—amyotrophic lateral sclerosis	0.00433	0.00836	CcSEcCtD
Atomoxetine—Malnutrition—Riluzole—amyotrophic lateral sclerosis	0.00431	0.00831	CcSEcCtD
Atomoxetine—HTR2A—hindbrain—amyotrophic lateral sclerosis	0.00427	0.012	CbGeAlD
Atomoxetine—HTR6—central nervous system—amyotrophic lateral sclerosis	0.00426	0.0119	CbGeAlD
Atomoxetine—Flatulence—Riluzole—amyotrophic lateral sclerosis	0.00424	0.00818	CcSEcCtD
Atomoxetine—Tension—Riluzole—amyotrophic lateral sclerosis	0.00423	0.00815	CcSEcCtD
Atomoxetine—Dysgeusia—Riluzole—amyotrophic lateral sclerosis	0.00422	0.00813	CcSEcCtD
Atomoxetine—Nervousness—Riluzole—amyotrophic lateral sclerosis	0.00418	0.00807	CcSEcCtD
Atomoxetine—Back pain—Riluzole—amyotrophic lateral sclerosis	0.00416	0.00803	CcSEcCtD
Atomoxetine—Muscle spasms—Riluzole—amyotrophic lateral sclerosis	0.00414	0.00799	CcSEcCtD
Atomoxetine—SLC6A2—brainstem—amyotrophic lateral sclerosis	0.00407	0.0114	CbGeAlD
Atomoxetine—Tremor—Riluzole—amyotrophic lateral sclerosis	0.00403	0.00778	CcSEcCtD
Atomoxetine—Agitation—Riluzole—amyotrophic lateral sclerosis	0.00396	0.00763	CcSEcCtD
Atomoxetine—CYP2D6—hindbrain—amyotrophic lateral sclerosis	0.00389	0.0109	CbGeAlD
Atomoxetine—Vertigo—Riluzole—amyotrophic lateral sclerosis	0.00387	0.00746	CcSEcCtD
Atomoxetine—Syncope—Riluzole—amyotrophic lateral sclerosis	0.00386	0.00745	CcSEcCtD
Atomoxetine—Palpitations—Riluzole—amyotrophic lateral sclerosis	0.0038	0.00734	CcSEcCtD
Atomoxetine—Loss of consciousness—Riluzole—amyotrophic lateral sclerosis	0.00378	0.0073	CcSEcCtD
Atomoxetine—Cough—Riluzole—amyotrophic lateral sclerosis	0.00376	0.00725	CcSEcCtD
Atomoxetine—Convulsion—Riluzole—amyotrophic lateral sclerosis	0.00373	0.0072	CcSEcCtD
Atomoxetine—Arthralgia—Riluzole—amyotrophic lateral sclerosis	0.00367	0.00707	CcSEcCtD
Atomoxetine—Myalgia—Riluzole—amyotrophic lateral sclerosis	0.00367	0.00707	CcSEcCtD
Atomoxetine—Chest pain—Riluzole—amyotrophic lateral sclerosis	0.00367	0.00707	CcSEcCtD
Atomoxetine—Anxiety—Riluzole—amyotrophic lateral sclerosis	0.00365	0.00705	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.00364	0.00702	CcSEcCtD
Atomoxetine—Dry mouth—Riluzole—amyotrophic lateral sclerosis	0.00359	0.00692	CcSEcCtD
Atomoxetine—Infection—Riluzole—amyotrophic lateral sclerosis	0.00349	0.00673	CcSEcCtD
Atomoxetine—Shock—Riluzole—amyotrophic lateral sclerosis	0.00346	0.00667	CcSEcCtD
Atomoxetine—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.00345	0.00665	CcSEcCtD
Atomoxetine—Tachycardia—Riluzole—amyotrophic lateral sclerosis	0.00343	0.00662	CcSEcCtD
Atomoxetine—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.00341	0.00658	CcSEcCtD
Atomoxetine—HTR2C—medulla oblongata—amyotrophic lateral sclerosis	0.0034	0.00954	CbGeAlD
Atomoxetine—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.0034	0.00655	CcSEcCtD
Atomoxetine—HTR6—brain—amyotrophic lateral sclerosis	0.00338	0.00948	CbGeAlD
Atomoxetine—Anorexia—Riluzole—amyotrophic lateral sclerosis	0.00335	0.00646	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.0032	0.00618	CcSEcCtD
Atomoxetine—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.00318	0.00613	CcSEcCtD
Atomoxetine—HTR1B—spinal cord—amyotrophic lateral sclerosis	0.00316	0.00887	CbGeAlD
Atomoxetine—Paraesthesia—Riluzole—amyotrophic lateral sclerosis	0.00316	0.00609	CcSEcCtD
Atomoxetine—SLC6A3—spinal cord—amyotrophic lateral sclerosis	0.00314	0.0088	CbGeAlD
Atomoxetine—Somnolence—Riluzole—amyotrophic lateral sclerosis	0.00312	0.00603	CcSEcCtD
Atomoxetine—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.00309	0.00597	CcSEcCtD
Atomoxetine—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.00305	0.00589	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00303	0.00585	CcSEcCtD
Atomoxetine—HTR2C—spinal cord—amyotrophic lateral sclerosis	0.00303	0.00851	CbGeAlD
Atomoxetine—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.00303	0.00584	CcSEcCtD
Atomoxetine—Pain—Riluzole—amyotrophic lateral sclerosis	0.00301	0.0058	CcSEcCtD
Atomoxetine—Constipation—Riluzole—amyotrophic lateral sclerosis	0.00301	0.0058	CcSEcCtD
Atomoxetine—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.0029	0.00559	CcSEcCtD
Atomoxetine—SLC6A4—spinal cord—amyotrophic lateral sclerosis	0.00288	0.00806	CbGeAlD
Atomoxetine—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.00287	0.00554	CcSEcCtD
Atomoxetine—SLC6A2—medulla oblongata—amyotrophic lateral sclerosis	0.00284	0.00796	CbGeAlD
Atomoxetine—Urticaria—Riluzole—amyotrophic lateral sclerosis	0.00279	0.00539	CcSEcCtD
Atomoxetine—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.00278	0.00536	CcSEcCtD
Atomoxetine—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.00278	0.00536	CcSEcCtD
Atomoxetine—HTR2A—embryo—amyotrophic lateral sclerosis	0.00267	0.00749	CbGeAlD
Atomoxetine—HTR1B—nervous system—amyotrophic lateral sclerosis	0.00267	0.00748	CbGeAlD
Atomoxetine—SLC6A3—nervous system—amyotrophic lateral sclerosis	0.00264	0.00742	CbGeAlD
Atomoxetine—HTR1D—nervous system—amyotrophic lateral sclerosis	0.00258	0.00724	CbGeAlD
Atomoxetine—HTR1B—central nervous system—amyotrophic lateral sclerosis	0.00257	0.0072	CbGeAlD
Atomoxetine—HTR2C—nervous system—amyotrophic lateral sclerosis	0.00256	0.00717	CbGeAlD
Atomoxetine—SLC6A3—central nervous system—amyotrophic lateral sclerosis	0.00255	0.00714	CbGeAlD
Atomoxetine—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.00252	0.00486	CcSEcCtD
Atomoxetine—SLC6A3—cerebellum—amyotrophic lateral sclerosis	0.00249	0.00698	CbGeAlD
Atomoxetine—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.00249	0.0048	CcSEcCtD
Atomoxetine—HTR1D—central nervous system—amyotrophic lateral sclerosis	0.00248	0.00697	CbGeAlD
Atomoxetine—HTR2C—central nervous system—amyotrophic lateral sclerosis	0.00246	0.0069	CbGeAlD
Atomoxetine—HTR2A—brainstem—amyotrophic lateral sclerosis	0.00245	0.00686	CbGeAlD
Atomoxetine—SLC6A4—nervous system—amyotrophic lateral sclerosis	0.00242	0.00679	CbGeAlD
Atomoxetine—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.0024	0.00464	CcSEcCtD
Atomoxetine—SLC6A4—central nervous system—amyotrophic lateral sclerosis	0.00233	0.00654	CbGeAlD
Atomoxetine—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.00232	0.00448	CcSEcCtD
Atomoxetine—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.00223	0.00431	CcSEcCtD
Atomoxetine—CYP2D6—brainstem—amyotrophic lateral sclerosis	0.00223	0.00625	CbGeAlD
Atomoxetine—Rash—Riluzole—amyotrophic lateral sclerosis	0.00222	0.00427	CcSEcCtD
Atomoxetine—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.00221	0.00427	CcSEcCtD
Atomoxetine—Headache—Riluzole—amyotrophic lateral sclerosis	0.0022	0.00425	CcSEcCtD
Atomoxetine—SLC6A2—nervous system—amyotrophic lateral sclerosis	0.00213	0.00598	CbGeAlD
Atomoxetine—Nausea—Riluzole—amyotrophic lateral sclerosis	0.00209	0.00403	CcSEcCtD
Atomoxetine—SLC6A2—central nervous system—amyotrophic lateral sclerosis	0.00205	0.00576	CbGeAlD
Atomoxetine—HTR1B—brain—amyotrophic lateral sclerosis	0.00204	0.00571	CbGeAlD
Atomoxetine—SLC6A3—brain—amyotrophic lateral sclerosis	0.00202	0.00567	CbGeAlD
Atomoxetine—HTR1D—brain—amyotrophic lateral sclerosis	0.00197	0.00553	CbGeAlD
Atomoxetine—HTR2C—brain—amyotrophic lateral sclerosis	0.00195	0.00548	CbGeAlD
Atomoxetine—SLC6A4—brain—amyotrophic lateral sclerosis	0.00185	0.00519	CbGeAlD
Atomoxetine—HTR2A—medulla oblongata—amyotrophic lateral sclerosis	0.00171	0.00479	CbGeAlD
Atomoxetine—SLC6A2—brain—amyotrophic lateral sclerosis	0.00163	0.00457	CbGeAlD
Atomoxetine—HTR2A—spinal cord—amyotrophic lateral sclerosis	0.00152	0.00427	CbGeAlD
Atomoxetine—HTR2A—nervous system—amyotrophic lateral sclerosis	0.00128	0.0036	CbGeAlD
Atomoxetine—HTR2A—central nervous system—amyotrophic lateral sclerosis	0.00123	0.00346	CbGeAlD
Atomoxetine—HTR2A—cerebellum—amyotrophic lateral sclerosis	0.00121	0.00338	CbGeAlD
Atomoxetine—CYP3A4—nervous system—amyotrophic lateral sclerosis	0.00119	0.00333	CbGeAlD
Atomoxetine—CYP2D6—nervous system—amyotrophic lateral sclerosis	0.00117	0.00328	CbGeAlD
Atomoxetine—CYP3A4—central nervous system—amyotrophic lateral sclerosis	0.00114	0.0032	CbGeAlD
Atomoxetine—CYP2D6—central nervous system—amyotrophic lateral sclerosis	0.00112	0.00315	CbGeAlD
Atomoxetine—CYP2D6—cerebellum—amyotrophic lateral sclerosis	0.0011	0.00308	CbGeAlD
Atomoxetine—Fenoprofen—PTGS2—amyotrophic lateral sclerosis	0.000991	0.138	CrCbGaD
Atomoxetine—HTR2A—brain—amyotrophic lateral sclerosis	0.00098	0.00275	CbGeAlD
Atomoxetine—CYP2D6—brain—amyotrophic lateral sclerosis	0.000893	0.0025	CbGeAlD
Atomoxetine—Ketoprofen—PTGS2—amyotrophic lateral sclerosis	0.000585	0.0814	CrCbGaD
Atomoxetine—NPY1R—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	0.000454	0.00386	CbGpPWpGaD
Atomoxetine—SLC6A4—NRF2 pathway—GSTP1—amyotrophic lateral sclerosis	0.000451	0.00383	CbGpPWpGaD
Atomoxetine—SLC6A3—Neuronal System—SLC1A2—amyotrophic lateral sclerosis	0.000448	0.0038	CbGpPWpGaD
Atomoxetine—CYP2D6—Melatonin metabolism and effects—APOE—amyotrophic lateral sclerosis	0.000443	0.00376	CbGpPWpGaD
Atomoxetine—SLC6A3—Transmission across Chemical Synapses—SLC6A1—amyotrophic lateral sclerosis	0.000443	0.00376	CbGpPWpGaD
Atomoxetine—SLC6A3—NRF2 pathway—SQSTM1—amyotrophic lateral sclerosis	0.000439	0.00373	CbGpPWpGaD
Atomoxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—C5AR1—amyotrophic lateral sclerosis	0.000429	0.00364	CbGpPWpGaD
Atomoxetine—HTR1D—Class A/1 (Rhodopsin-like receptors)—C5AR1—amyotrophic lateral sclerosis	0.000426	0.00361	CbGpPWpGaD
Atomoxetine—SLC6A2—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	0.000422	0.00358	CbGpPWpGaD
Atomoxetine—HTR1B—Class A/1 (Rhodopsin-like receptors)—C5AR1—amyotrophic lateral sclerosis	0.000417	0.00354	CbGpPWpGaD
Atomoxetine—SLC6A4—SIDS Susceptibility Pathways—BDNF—amyotrophic lateral sclerosis	0.000412	0.00349	CbGpPWpGaD
Atomoxetine—SLC6A3—Neuronal System—NEFL—amyotrophic lateral sclerosis	0.000409	0.00347	CbGpPWpGaD
Atomoxetine—SLC6A2—SLC-mediated transmembrane transport—SLC6A1—amyotrophic lateral sclerosis	0.000405	0.00344	CbGpPWpGaD
Atomoxetine—SLC6A3—SLC-mediated transmembrane transport—SLC1A3—amyotrophic lateral sclerosis	0.000403	0.00342	CbGpPWpGaD
Atomoxetine—SLC6A2—NRF2 pathway—GSTP1—amyotrophic lateral sclerosis	0.000388	0.00329	CbGpPWpGaD
Atomoxetine—NPY1R—GPCR ligand binding—C3—amyotrophic lateral sclerosis	0.000387	0.00328	CbGpPWpGaD
Atomoxetine—SLC6A3—Neuronal System—SLC1A3—amyotrophic lateral sclerosis	0.000381	0.00323	CbGpPWpGaD
Atomoxetine—SLC6A3—Neuronal System—CHAT—amyotrophic lateral sclerosis	0.000381	0.00323	CbGpPWpGaD
Atomoxetine—CYP2C19—Arachidonic acid metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000379	0.00321	CbGpPWpGaD
Atomoxetine—SLC6A3—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	0.000374	0.00317	CbGpPWpGaD
Atomoxetine—SLC6A3—SLC-mediated transmembrane transport—SLC6A1—amyotrophic lateral sclerosis	0.000359	0.00305	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.000354	0.00301	CbGpPWpGaD
Atomoxetine—SLC6A3—NRF2 pathway—GSTP1—amyotrophic lateral sclerosis	0.000343	0.00291	CbGpPWpGaD
Atomoxetine—CYP2C19—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.000343	0.00291	CbGpPWpGaD
Atomoxetine—SLC6A3—Neuronal System—SLC6A1—amyotrophic lateral sclerosis	0.000339	0.00288	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000333	0.00283	CbGpPWpGaD
Atomoxetine—HTR6—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	0.000327	0.00277	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	0.000324	0.00275	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	0.000317	0.00269	CbGpPWpGaD
Atomoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—C5AR1—amyotrophic lateral sclerosis	0.000316	0.00268	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.000316	0.00268	CbGpPWpGaD
Atomoxetine—CYP2D6—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.000315	0.00268	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.000306	0.00259	CbGpPWpGaD
Atomoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—C5AR1—amyotrophic lateral sclerosis	0.000274	0.00233	CbGpPWpGaD
Atomoxetine—SLC6A2—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	0.000272	0.00231	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	0.000272	0.0023	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	0.000268	0.00228	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	0.000264	0.00224	CbGpPWpGaD
Atomoxetine—HTR2A—SIDS Susceptibility Pathways—BDNF—amyotrophic lateral sclerosis	0.000248	0.0021	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	0.000241	0.00205	CbGpPWpGaD
Atomoxetine—SLC6A3—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	0.000241	0.00204	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	0.000241	0.00204	CbGpPWpGaD
Atomoxetine—HTR1D—G alpha (i) signalling events—C3—amyotrophic lateral sclerosis	0.000234	0.00198	CbGpPWpGaD
Atomoxetine—SLC6A2—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	0.000231	0.00196	CbGpPWpGaD
Atomoxetine—SLC6A2—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	0.000231	0.00196	CbGpPWpGaD
Atomoxetine—HTR1B—G alpha (i) signalling events—C3—amyotrophic lateral sclerosis	0.000229	0.00194	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	0.000224	0.0019	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	0.000224	0.0019	CbGpPWpGaD
Atomoxetine—NPY1R—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	0.000218	0.00185	CbGpPWpGaD
Atomoxetine—CYP2C19—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	0.000214	0.00181	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	0.000211	0.00179	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	0.000209	0.00177	CbGpPWpGaD
Atomoxetine—CYP3A4—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.000206	0.00175	CbGpPWpGaD
Atomoxetine—SLC6A2—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	0.000206	0.00175	CbGpPWpGaD
Atomoxetine—SLC6A4—SIDS Susceptibility Pathways—CASP3—amyotrophic lateral sclerosis	0.000206	0.00174	CbGpPWpGaD
Atomoxetine—SLC6A3—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	0.000205	0.00174	CbGpPWpGaD
Atomoxetine—SLC6A3—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	0.000205	0.00174	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—C3—amyotrophic lateral sclerosis	0.000198	0.00168	CbGpPWpGaD
Atomoxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	0.000187	0.00159	CbGpPWpGaD
Atomoxetine—HTR1D—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	0.000186	0.00158	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	0.000185	0.00157	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	0.000184	0.00157	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	0.000183	0.00155	CbGpPWpGaD
Atomoxetine—SLC6A3—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	0.000182	0.00155	CbGpPWpGaD
Atomoxetine—HTR1B—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	0.000182	0.00154	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	0.000179	0.00152	CbGpPWpGaD
Atomoxetine—SLC6A4—SIDS Susceptibility Pathways—VEGFA—amyotrophic lateral sclerosis	0.000174	0.00148	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	0.000173	0.00147	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	0.000168	0.00142	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	0.000166	0.00141	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	0.000165	0.0014	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	0.000163	0.00138	CbGpPWpGaD
Atomoxetine—CYP2C19—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.000153	0.0013	CbGpPWpGaD
Atomoxetine—CYP2C19—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	0.000151	0.00128	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	0.000145	0.00123	CbGpPWpGaD
Atomoxetine—HTR6—GPCR ligand binding—C3—amyotrophic lateral sclerosis	0.000143	0.00121	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR ligand binding—C3—amyotrophic lateral sclerosis	0.000142	0.0012	CbGpPWpGaD
Atomoxetine—CYP2D6—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.000141	0.0012	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	0.000141	0.0012	CbGpPWpGaD
Atomoxetine—CYP2D6—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	0.000139	0.00118	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR ligand binding—C3—amyotrophic lateral sclerosis	0.000139	0.00118	CbGpPWpGaD
Atomoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	0.000138	0.00117	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	0.000136	0.00115	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	0.000133	0.00113	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.000131	0.00111	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.00013	0.0011	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.000127	0.00108	CbGpPWpGaD
Atomoxetine—HTR2A—SIDS Susceptibility Pathways—CASP3—amyotrophic lateral sclerosis	0.000124	0.00105	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	0.000123	0.00105	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000123	0.00104	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000122	0.00103	CbGpPWpGaD
Atomoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	0.00012	0.00102	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000119	0.00101	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	0.000118	0.001	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000118	0.000997	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000118	0.000997	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—C3—amyotrophic lateral sclerosis	0.000117	0.000994	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.000116	0.000988	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.000116	0.000981	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.000113	0.00096	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.000113	0.000957	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.000112	0.00095	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	0.00011	0.00093	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.00011	0.00093	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—APOE—amyotrophic lateral sclerosis	0.000109	0.000926	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000108	0.000917	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000108	0.000917	CbGpPWpGaD
Atomoxetine—SLC6A4—Circadian rythm related genes—TP53—amyotrophic lateral sclerosis	0.000108	0.000913	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000108	0.000912	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	0.000107	0.00091	CbGpPWpGaD
Atomoxetine—HTR2A—SIDS Susceptibility Pathways—VEGFA—amyotrophic lateral sclerosis	0.000105	0.000891	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—C3—amyotrophic lateral sclerosis	0.000105	0.000891	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	0.0001	0.00085	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.0001	0.000848	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	9.94e-05	0.000843	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	9.9e-05	0.00084	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—VAPA—amyotrophic lateral sclerosis	9.89e-05	0.000839	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	9.83e-05	0.000834	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	9.73e-05	0.000826	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	9.62e-05	0.000816	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	9.62e-05	0.000816	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—FIG4—amyotrophic lateral sclerosis	9.4e-05	0.000797	CbGpPWpGaD
Atomoxetine—CYP3A4—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	9.23e-05	0.000783	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—SACM1L—amyotrophic lateral sclerosis	9.19e-05	0.00078	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—C3—amyotrophic lateral sclerosis	9.12e-05	0.000774	CbGpPWpGaD
Atomoxetine—CYP3A4—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	9.1e-05	0.000772	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	9.05e-05	0.000768	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	9.02e-05	0.000765	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—FIG4—amyotrophic lateral sclerosis	8.64e-05	0.000733	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—VCP—amyotrophic lateral sclerosis	8.58e-05	0.000728	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—DAO—amyotrophic lateral sclerosis	8.5e-05	0.000721	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	8.36e-05	0.000709	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	8.31e-05	0.000705	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	8.28e-05	0.000703	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	8.22e-05	0.000697	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	8.06e-05	0.000684	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	8.05e-05	0.000683	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	8e-05	0.000678	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	7.86e-05	0.000667	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	7.83e-05	0.000664	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—DAO—amyotrophic lateral sclerosis	7.82e-05	0.000663	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—VCP—amyotrophic lateral sclerosis	7.45e-05	0.000632	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	7.38e-05	0.000626	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—C3—amyotrophic lateral sclerosis	7.32e-05	0.000621	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	7.29e-05	0.000619	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—C3—amyotrophic lateral sclerosis	7.26e-05	0.000616	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	7.21e-05	0.000612	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—C3—amyotrophic lateral sclerosis	7.11e-05	0.000603	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—VAPB—amyotrophic lateral sclerosis	7.07e-05	0.0006	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—TPK1—amyotrophic lateral sclerosis	7.07e-05	0.0006	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	6.94e-05	0.000589	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	6.8e-05	0.000577	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	6.75e-05	0.000573	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	6.61e-05	0.000561	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	6.56e-05	0.000556	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—VAPA—amyotrophic lateral sclerosis	6.47e-05	0.000549	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PLB1—amyotrophic lateral sclerosis	6.44e-05	0.000547	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	6.41e-05	0.000543	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	6.38e-05	0.000541	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	6.33e-05	0.000537	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	6.33e-05	0.000537	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	6.2e-05	0.000526	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	6.1e-05	0.000517	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	6.08e-05	0.000516	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	6.03e-05	0.000512	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—SACM1L—amyotrophic lateral sclerosis	6.01e-05	0.00051	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—GSR—amyotrophic lateral sclerosis	5.94e-05	0.000504	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	5.93e-05	0.000503	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PLB1—amyotrophic lateral sclerosis	5.92e-05	0.000503	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	5.91e-05	0.000501	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	5.89e-05	0.0005	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—FIG4—amyotrophic lateral sclerosis	5.65e-05	0.00048	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—GSR—amyotrophic lateral sclerosis	5.47e-05	0.000464	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	5.41e-05	0.000459	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—C3—amyotrophic lateral sclerosis	5.39e-05	0.000457	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	5.3e-05	0.000449	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	5.2e-05	0.000441	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	5.16e-05	0.000438	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	5.15e-05	0.000437	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—DAO—amyotrophic lateral sclerosis	5.11e-05	0.000434	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	5.06e-05	0.000429	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	5.01e-05	0.000425	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	4.89e-05	0.000415	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CHAT—amyotrophic lateral sclerosis	4.88e-05	0.000414	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	4.85e-05	0.000412	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	4.75e-05	0.000403	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	4.7e-05	0.000399	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—C3—amyotrophic lateral sclerosis	4.68e-05	0.000397	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CHAT—amyotrophic lateral sclerosis	4.49e-05	0.000381	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	4.48e-05	0.00038	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	4.45e-05	0.000378	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—TP53—amyotrophic lateral sclerosis	4.45e-05	0.000377	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	4.35e-05	0.000369	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—C3—amyotrophic lateral sclerosis	4.32e-05	0.000367	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—C3—amyotrophic lateral sclerosis	4.29e-05	0.000364	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—C3—amyotrophic lateral sclerosis	4.2e-05	0.000356	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	4.08e-05	0.000346	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—APOE—amyotrophic lateral sclerosis	4.02e-05	0.000341	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—APOE—amyotrophic lateral sclerosis	3.99e-05	0.000339	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—APOE—amyotrophic lateral sclerosis	3.91e-05	0.000332	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	3.89e-05	0.00033	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PLB1—amyotrophic lateral sclerosis	3.87e-05	0.000329	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	3.83e-05	0.000325	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	3.6e-05	0.000306	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GSR—amyotrophic lateral sclerosis	3.57e-05	0.000303	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	3.33e-05	0.000282	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	3.33e-05	0.000282	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	3.3e-05	0.00028	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	3.23e-05	0.000274	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—C3—amyotrophic lateral sclerosis	3.18e-05	0.00027	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	3.13e-05	0.000265	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	3.05e-05	0.000259	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—APOE—amyotrophic lateral sclerosis	2.96e-05	0.000251	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CHAT—amyotrophic lateral sclerosis	2.94e-05	0.000249	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—C3—amyotrophic lateral sclerosis	2.76e-05	0.000235	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.62e-05	0.000223	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—APOE—amyotrophic lateral sclerosis	2.57e-05	0.000218	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	2.56e-05	0.000217	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	2.54e-05	0.000216	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	2.49e-05	0.000211	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	2.45e-05	0.000208	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	2.42e-05	0.000205	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.41e-05	0.000205	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.41e-05	0.000205	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	2.4e-05	0.000204	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	2.35e-05	0.000199	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.22e-05	0.000188	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	2.17e-05	0.000184	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	2.16e-05	0.000183	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	2.13e-05	0.00018	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	2.11e-05	0.000179	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—APOE—amyotrophic lateral sclerosis	1.98e-05	0.000168	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.89e-05	0.00016	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—APOE—amyotrophic lateral sclerosis	1.82e-05	0.000155	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.78e-05	0.000151	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.64e-05	0.000139	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.64e-05	0.000139	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.63e-05	0.000138	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.6e-05	0.000136	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.59e-05	0.000135	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.58e-05	0.000134	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.55e-05	0.000131	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.45e-05	0.000123	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.39e-05	0.000118	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.36e-05	0.000115	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.25e-05	0.000106	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.21e-05	0.000103	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—APOE—amyotrophic lateral sclerosis	1.19e-05	0.000101	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.05e-05	8.9e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PTGS2—amyotrophic lateral sclerosis	8.17e-06	6.94e-05	CbGpPWpGaD
